Banking on hope, swayed by hype? Hydroxychloroquine in the time of Covid-19

Banking on hope, swayed by hype? Hydroxychloroquine in the time of Covid-19
As coronavirus deaths amassed and already stretched health care systems in Europe, and the United States groaned with the added weight of the pandemic, the FDA and EMA agencies adopted contradictory tones over the use of a pair of decades-old malaria drugs to fight the virus — epitomizing the desperation to combat an uncharted disease.

“This is just another example that points to the fact that while EMA and FDA oftentimes take the same position, they also take contrary positions,” said Peter Pitts, who served as the FDA’s associate commissioner for external relations between 2002 and 2004. “We are addressing Covid-19 in a variety of ways, and so is the EMA — the circles are concentric, but they are not identical.”
Sign Up for Our Email Newsletter

RECENT NEWS

It's time to kill the patient COVID-19 tax

It's time to kill the patient COVID-19 tax

With a pandemic ravaging the nation, now isn’t the time to hurt patients’ ability to access critical medicines....  Read more

Why Russia became the 'sudden' coronavirus epicenter in Europe

Why Russia became the 'sudden' coronavirus epicenter in Europe

And after a relatively few cases were documented in March, Russia now has the second-fastest rate of new infections world...  Read more

Former FDA Associate Commissioner Peter Pitts says we should be ‘cautiously optimistic’ about the early positive results from Moderna vaccine

Former FDA Associate Commissioner Peter Pitts says we should be ‘cautiously optimistic’ about the early positive results from Moderna vaccine

Peter Pitts appears on KTLA 5 to discuss COVID-19 and the Moderna vaccine...  Read more

DRUGWONKS BLOG